ERBB2 and cancer: Common EGFR inhibitors used in cancer treatment include anti-EGFR mAbs, such as cetuximab and panitumumab, EGFR TKIs like gefitinib, erlotinib, and afatinib, as well as HER2 mAbs trastuzumab and pertuzumab, and HER2 TKI lapatinib.